The World Health Organization (WHO) said Monday that it has agreed to a plan to roll out 120 million rapid-diagnostic tests for the coronavirus.
Along with its leading partners, WHO aims to help lower- and middle-income countries make up ground in a testing gap with richer countries.
The antigen-based rapid diagnostic tests, for which WHO issued an emergency-use listing last week, cost around €4.28.
The programme, which initially requires €513.9 million, is not fully funded yet but is to get started as early as next month to provide better access to areas that are harder to reach with the PCR tests often in many wealthier nations.
The rapid tests look for antigens, or proteins found on the surface of the virus. They are generally considered less accurate — though much faster — than higher-grade genetic tests, known as PCR tests.
The PCR tests require processing with speciality lab equipment and chemicals and have a turnaround that typically takes several days to deliver results to patients.
WHO Director-General Tedros Adhanom Ghebreyesus hailed the program as “good news” in the fight against COVID-19.
“These tests provide reliable results in approximately 15 to 30 minutes, rather than hours or days, at a lower price with less sophisticated equipment,” he said. “This will enable the expansion of testing, particularly in hard-to-reach areas that do not have lab facilities or enough trained health workers to carry out PCR tests.”
“We have an agreement, we have seed funding and now we need the full amount of funds to buy these tests,” he said, without giving more details.
Dr Catharina Boehme, chief executive of a non-profit group called the Foundation for Innovative New Diagnostics, said the rollout would take place in 20 countries in Africa and would rely on the support of groups including the Clinton Health Access Initiative. She said the diagnostic tests will be provided by SD Biosensor and Abbott.
Peter Sands, the executive director of the Global Fund, a partnership that works to end epidemics, said it would make an initial €42.8 million available from its COVID-19 response mechanism.
He said the deployment of the quality antigen rapid diagnostic tests will be a “significant step” in helping to contain and combat the coronavirus.
“They’re not a silver bullet, but hugely valuable as a complement to PCR tests, since although they are less accurate, they’re much faster, cheaper and don’t require a lab,” he said.
Many rich countries have also faced problems rolling out accurate tests, and testing itself is no panacea — countries like France and the United States have all faced backlogs and hiccups at times, and rapid tests in Britain and Spain turned out to be inaccurate.
But rolling out testing in poorer countries aims to help health care workers get a better grip on where the virus is circulating, in hopes of following up with containment and other measures to stop it.
Sands said high-income countries are currently carrying out 292 tests per day per 100,000 people, while the lowest-income countries were conducting 14 per 100,000 people.
He said the 120 million tests would represent a “massive increase” in testing, but were still a fraction of what is needed in those countries.
